'Stress hyperglycemia ratio and in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes.

OBJECTIVE: To evaluate the impact of stress hyperglycemia on the in-hospital prognosis in non-surgical patients with heart failure and type 2 diabetes. RESEARCH DESIGN AND METHODS: We identified non-surgical hospitalized patients with heart failure and type 2 diabetes from a large electronic medical record-based database of diabetes in China (WECODe) from 2011 to 2019. We estimated stress hyperglycemia using the stress hyperglycemia ratio (SHR) and its equation, say admission blood glucose/[(28.7 × HbA1c)- 46.7]. The primary outcomes included the composite cardiac events (combination of death during hospitalization, requiring cardiopulmonary resuscitation, cardiogenic shock, and the new episode of acute heart failure during hospitalization), major acute kidney injury (AKI stage 2 or 3), and major systemic infection. RESULTS: Of 2875 eligible Chinese adults, SHR showed U-shaped associations with composite cardiac events, major AKI, and major systemic infection. People with SHR in the third tertile (vs those with SHR in the second tertile) presented higher risks of composite cardiac events ([odds ratio, 95% confidence interval] 1.89, 1.26 to 2.87) and major AKI (1.86, 1.01 to 3.54). In patients with impaired kidney function at baseline, both SHR in the first and third tertiles anticipated higher risks of major AKI and major systemic infection. CONCLUSIONS: Both high and low SHR indicates poor prognosis during hospitalization in non-surgical patients with heart failure and type 2 diabetes.

Dihydromyricetin Attenuates Metabolic Syndrome And Improves Insulin Sensitivity By Upregulating Insulin Receptor Substrate-1 (Y612) Tyrosine Phosphorylation In db/db Mice.

PURPOSE: Dihydromyricetin (DHM), the main bioactive flavonoid in vine tea, exerts multiple health beneficial effects. This work aimed to identify whether a naturally derived flavonoid product, DHM, can significantly attenuate metabolic syndrome and improve insulin sensitivity. METHODS: 10-week-old db/db mice were randomly assigned to receive the antidiabetic agent metformin (Met, 50 mg/kg BW), DHM (1.0 g and 0.5 g/kg BW) or placebo and were simultaneously fed a high-fat diet for 8 weeks. The general status of the animals was observed and recorded daily, body weight and blood glucose levels were measured weekly, during the experimental period. On day 55, the oral glucose tolerance test (OGTT) was performed. After OGTT, all animals were anesthetized and sacrificed by cervical decapitation. Blood samples were collected in tubes to detect plasma insulin and the biochemical parameters of lipid metabolism. Pancreas histological changes and islet fibrosis were demonstrated by H&E staining and Masson staining, respectively. Moreover, the expression of insulin receptor substrate-1 and phosphorylated insulin receptor substrate-1 in the insulin signaling pathway was detected by Western blot assay. RESULTS: The oral administration of DHM (1.0 g and 0.5 g/kg BW) reduced the fasting blood glucose, serum insulin, and glycated hemoglobin levels and the insulin resistance (HOMA-IR) index. Furthermore, DHM intervention decreased body weight and the serum lipid profile. In addition, DHM treatment also markedly decreased the relative abdominal fat weight. Western blot analysis indicated that DHM upregulated the IRS-1 (Y612) tyrosine phosphorylation, improving insulin resistance. Treatment with dihydromyricetin attenuated the progression of insulin resistance and pancreatic fibrosis in fatty db/db mice. CONCLUSION: In summary, we determined the antimetabolic syndrome effect of DHM in db/db obese mice. DHM upregulates the IRS-1 (Y612) tyrosine phosphorylation, improving insulin resistance. Therefore, DHM is a promising therapeutic candidate for the control of metabolic syndrome.

Misfit strain-induced energy dissipation for graphene/MoS2 heterostructure nanomechanical resonators.

Misfit strain is inevitable in various heterostructures like the graphene/MoS2 van der Waals heterostructure. Although the misfit strain effect on electronic and other physical properties have been well studied, it is still unclear how the misfit strain will affect the performance of the nanomechanical resonator based on the graphene/MoS2 heterostructure. By performing molecular dynamics simulations, we disclose a misfit strain-induced decoupling phenomenon between the graphene layer and the MoS2 layer during the resonant oscillation of the heterostructure. A direct relationship between the misfit strain and the decoupling mechanism is successfully established through the retraction force analysis. We further suggest to use the graphene/MoS2/graphene sandwich heterostructure for the nanomechanical resonator application, which is able to prevent the misfit strain-related decoupling phenomenon. These results provide valuable information for the future application of the graphene/MoS2 heterostructure in the nanomechanical resonator field.

Nanomechanical resonators based on group IV element monolayers.

We perform molecular dynamics simulations to investigate the energy dissipation of the resonant oscillation for the group IV monolayers of puckered configuration, in which the oscillation is driven with different actuation velocities. We find that, in the moderate actuation velocity regime, the nonlinear coupling between the resonant oscillation mode and other high-frequency modes will lead to the non-resonant motion of the system. For the larger actuation velocity, the effective strain generated during the resonant oscillating causes a structural transition from the puckered configuration into the planar configuration, which is a characteristic energy dissipation mechanism for the resonant oscillation of these group IV puckered monolayers. Our findings shed light on mechanical applications of the group IV monolayers in the nanomechanical resonator field.

Correction: APTES assisted surface heparinization of polylactide porous membranes for improved hemocompatibility.

[This corrects the article DOI: 10.1039/C6RA04525A.].

Association of Platelet Membrane Glycoprotein HPA-2a/b, GP VI T13254C, and GP Ibα VNTR Polymorphisms with Risk of Coronary Artery Disease: A Meta-Analysis.

BACKGROUND AND AIMS: Recently, controversial results have been reported regarding the association of the polymorphisms of platelet membrane glycoproteins (HPA-2a/b, GP VI T13254C, and GP Ibα VNTR) with coronary artery disease (CAD). We performed this meta-analysis to further assess the polymorphisms of platelet membrane glycoproteins with a risk of CAD. METHODS: A systematic electronic literature search was conducted in Embase, Cochrane Library, PubMed, and the Chinese Biomedical Literature Database (CBM). Analyses were performed using the Cochrane software package Review Manager 5.2 and Stata 12.0 software package. RESULTS: Twenty-nine full-text articles were included in the meta-analysis. Based on random-effects meta-analysis, a significant association between the HPA-2a/b polymorphism and CAD was identified (allele model: odds ratio = 1.43, 95% confidence interval = 1.07-1.91; dominant genetic model: odds ratio = 1.57, 95% confidence interval = 1.08-2.28). Our study showed no association between the GP VI T13254C polymorphism and CAD in either a random-effects model or a fixed-effects model. Furthermore, there was no evidence to suggest that the GP Ibα VNTR polymorphism was associated with CAD in any of the genetic analysis models. CONCLUSIONS: The HPA-2a/b polymorphism correlated significantly with a risk of CAD, and the HPA-2b allele and the HPA-2ab + HPA-2bb genotype may increase the risk of CAD. There was no evidence to suggest that polymorphisms of GP VI T13254C and GP Ibα VNTR were associated with CAD.

[Ten-day sequential therapy for Helicobacter pylori eradication in children: a systematic review of randomized controlled trials].

OBJECTIVE: To assess the efficacy and safety of 10-day sequential therapy for Helicobacter pylori (H.pylori) eradication in children. METHODS: The databases of Cochrane Central Register of Controlled Trials (CENTRAL, 2013,N01), Medline, Embase, OVID, Chinese Biological Medicine database (CBMDisc), CNKI, Chinese VIP and WANFANG (all from 2000-2013) were searched. And manual searches were performed for the relevant journals and conference proceedings. Prospective, randomized controlled trials of 10-day sequential therapy for H.pylori eradication in children were selected. The systematic review was conducted with the method recommended by The Cochrane Collaboration. RESULTS: Fifteen trials with a total of 1348 patients were included for analysis. The meta-analysis showed: (1) H.pylori eradication rates: 10-day sequential therapy were superior to triple therapy (80.78% (521/645) vs 69.84% (491/703), OR 2.13, 95%CI: 1.62-2.80, P < 0.01). It was also superior to 7-day and 10-day standard triple therapy (86.03% (271/315) vs 73.77% (225/305), 79.04% (181/229) vs 65.19% (176/270); OR 2.23, 2.11; 95%CI:1.47-3.36, 1.37-3.24;both P < 0.01) . There were non-superior to 14-day standard triple therapy (73.97% (108/146) vs 70.31% (90/128), OR 1.87, 95%CI: 0.46-7.69, P = 0.38). (2) Adverse effect rate: adverse events were similar between sequential and standard triple therapies (P = 0.58). CONCLUSION: The 10-day sequential therapy may be a new effective and safe option in treatment of H.pylori infections in children.